Table 1.
Demographics and clinicopathologic information among HRAS-mutant salivary cancer patients receiving tipifarnib
| Characteristic | All patients N = 13a |
|---|---|
| Age at diagnosis (median) | 58 (34–75) |
| Gender | |
| Female | 2 (15) |
| Male | 11 (85) |
| ECOG performance status | |
| 0–1 | 13 (100) |
| Ethnicity & Race | |
| White | 10 (77)b |
| Asian | 2 (15) |
| Black | 1 (8) |
| Site of Primary Disease | |
| Parotid gland | 12 (92) |
| Minor salivary gland | 1 (8) |
| Histologic subtype (high grade) | |
| Salivary duct carcinoma | 4 (31) |
| Myoepithelial-epithelial carcinoma | 4 (31) |
| Mucoepidermoid carcinoma | 1 (8) |
| Acinic cell carcinoma | 1 (8) |
| Oncocytic carcinoma | 1 (8) |
| Adenocarcinoma | 1 (8) |
| Carcinoma ex pleomorphic adenoma | 1 (8) |
| Initial Disease Stagingc | |
| Stage I, II | 2 (15) |
| Stage III, IVA-C | 11 (85)d |
| Initial or Primary Therapy | |
| Surgery alone | 1 (8) |
| Surgery + radiation (RT) | 6 (46) |
| Surgery + chemoradiation (CRT) | 4 (31) |
| Systemic therapy | 2 (15) |
| Median time to recurrence (in months) | 22.0 (4–81) |
| # of Lines of Prior Therapy for Advanced Disease | |
| 1–2 | 9 (69) |
| 3+ | 4 (31) |
a
parentheses indicate % except for age which represents range;
b
no patients identified as Hispanic;
c
American Joint Committee on Cancer (AJCC) 8th edition Staging (2017);
d
N=2 had metastatic disease at initial presentation; ECOG = Eastern Cooperative Oncology Group